Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - methyldopa (anhydrous) - oral tablet - 250mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methyldopa (anhydrous) - oral tablet - 125mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methyldopa (anhydrous) - oral tablet - 250mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methyldopa (anhydrous) - oral tablet - 500mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - methyldopa (anhydrous) - oral tablet - 250mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - methyldopa (anhydrous) - oral tablet - 250mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - methyldopa (anhydrous) - oral tablet - 250mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - methyldopa anhydrous - oral tablet - 125mg

Estados Unidos - inglés - NLM (National Library of Medicine)

physicians total care, inc. - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - methyldopa 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

Estados Unidos - inglés - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg